Invitrogen Corporation and Solexa, Inc. have announced a collaboration through which Invitrogen will supply many of the reagents for Solexa’s sequencing, gene expression, and small RNA analysis kits designed to be used with the Solexa Genome Analysis System.
Solexa expects the Solexa Genome Analysis System to reduce the cost and improve the speed of a broad range of applications, including whole genome human sequencing and expression profiling.
Solexa claims that, its platform, which leverages the company’s proprietary Clonal Single Molecule Array™ technology and reversible-terminator chemistry, has the versatility and scalability to address researchers’ needs in a range of settings, including core facilities, genome centers, and individual laboratories.
"As Solexa advances along the path to broadly commercialize our genetic analysis platform with the goal of enabling customers to re-sequence human genomes for $100,000, we are committed to working with leading companies in the life science business," said John West, chief executive officer of Solexa.
"Our customers want the best reagents to use on our platforms, and with Invitrogen’s well-earned reputation for manufacturing and delivering consistently high quality reagents, we are confident that our customers’ expectations will be met."
"Our relationship with Solexa will allow us to be a significant player in an area that could change the shape of human medicine," said Claude Benchimol, Invitrogen’s Senior Vice President, Research and Development.
"Furthermore, by supplying the majority of reagents in these Solexa-branded kits, we continue to demonstrate our leadership role as an OEM supplier."
"With our flexibility, manufacturing capability and breadth of raw materials, we can readily handle a variety of kits for our manufacturing partners such as the ones that are needed to run on Solexa’s platform."